Imfinzi® Injection for Lung Cancer

Imfinzi is an immune checkpoint inhibitor used in several cancers, including certain lung and biliary tract cancers. This page explains how the treatment works, who may be eligible, and how clinic-administered dosing is scheduled. You will also find practical access details and what you might expect to pay without insurance.

What Imfinzi Is and How It Works

Imfinzi® (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody given by intravenous infusion. By inhibiting PD-L1, it can help T cells recognize and attack tumor cells. Border Free Health connects U.S. patients with licensed Canadian partner pharmacies; prescriptions are verified with prescribers before dispensing. When appropriate, our team coordinates US delivery from Canada through trusted channels.

This medicine is used alone or with other anticancer agents, depending on the diagnosis and stage. Regimens are defined in the official prescribing information. Infusions occur in a clinic or infusion center under professional supervision.

We present current Imfinzi price information alongside guidance about access and safety so you can discuss options with your clinician.

Who It’s For

The treatment is used for adults with certain lung cancers after chemoradiation or in combination with chemotherapy. It is also used with chemotherapy for some biliary tract cancers, and with specific immunotherapy partners for selected liver cancer cases. Specific use depends on tumor type, stage, biomarkers, and prior therapy as outlined on the label.

Patients with permanently discontinued prior immunotherapy due to severe immune-related side effects, active autoimmune disease requiring systemic treatment, or a history of organ transplant may not be candidates. Your clinician will review risks such as prior pneumonitis, active infection, and pregnancy plans before starting therapy. Imfinzi for lung cancer should be guided strictly by approved indications and your care team’s judgment.

Dosage and Usage

Durvalumab lung cancer regimens differ by indication and whether it is used alone or with other medicines. Maintenance schedules often follow induction therapy given with chemotherapy, but timing varies by diagnosis. Infusions are administered by trained staff, with monitoring during and after the drip for reactions.

Administration tips you may hear from your infusion team:

• Arrive hydrated and with recent lab work, if requested by your clinic.
• Report new symptoms, such as cough, shortness of breath, diarrhea, rash, or fatigue.
• Tell staff about any new medicines, including over-the-counter products.
• Stay for observation after the infusion if the center requires it.

Dosing intervals and cycle counts follow the official label and your oncology plan. Do not change or delay treatment on your own. If questions arise, contact your clinic promptly.

Strengths and Forms

The therapy is supplied as a sterile solution for IV infusion in single-dose vials. Two vial sizes are commonly used for weight-based or fixed dosing in adults. Exact vial selection is determined by your infusion center and the prescribed regimen. Availability can vary by program and location.

If you compare presentations across programs, your care team can explain how vial sizes align with your planned dose and infusion schedule.

Missed Dose and Timing

If an infusion is missed, clinics generally reschedule as soon as feasible and adjust the calendar based on the oncology plan. Follow your center’s guidance rather than skipping ahead. Do not attempt to “make up” a dose without clinical direction. Timing can change if you have side effects or intercurrent illness. Your team will advise when to resume.

Storage and Travel Basics

Clinics and infusion centers store and prepare vials according to strict standards. Patients typically do not handle or store this medicine at home. If you travel for care, bring your appointment details, a medication list, and contact information for your oncology team. Allow extra time for check-in and any required lab tests. We support temperature-controlled handling when required within the supply chain.

Pen Handling and Sharps Disposal

This therapy is not supplied as a pen or self-injector. Infusions are prepared and administered by healthcare professionals, so at-home sharps handling is not required.

Benefits

As a PD-L1 inhibitor, this treatment can support an antitumor immune response in eligible cancers. It may be used after chemoradiation to help maintain control in selected lung cancer settings or paired with chemotherapy to treat certain advanced diseases. Infusion-based scheduling can simplify adherence, since each visit includes clinical assessment, lab review when needed, and administration under supervision.

Side Effects and Safety

Common effects can include fatigue, cough, decreased appetite, nausea, diarrhea, constipation, rash, and musculoskeletal pain. Infusion-related reactions may occur during or shortly after the drip. Immune-mediated effects can involve the lungs, liver, intestines, kidneys, skin, endocrine organs, or other systems.

• Common: fatigue, cough, rash, itching, diarrhea, nausea
• Occasional: joint pain, headache, constipation, decreased appetite
• Serious: pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, myocarditis, severe rash, infusion reactions

Call your clinician immediately for new or worsening symptoms, especially shortness of breath, severe abdominal pain, jaundice, confusion, rapid heartbeat, or vision changes. Use in pregnancy can harm a developing baby; discuss contraception and pregnancy plans before treatment. Your care team will monitor labs and symptoms throughout therapy.

Drug Interactions and Cautions

Tell your clinician about all medicines and supplements. Systemic immunosuppressants may blunt immune responses to checkpoint inhibitors. Corticosteroids are sometimes required to manage immune-related side effects, but long-term high-dose use can affect treatment considerations. Avoid live vaccines during therapy and for a period after as directed by your oncology team. Pre-existing autoimmune disease requires careful risk–benefit discussion.

What to Expect Over Time

Your infusion schedule may begin with combination therapy and transition to maintenance if indicated. Clinic visits can include symptom review, lab monitoring, and imaging at intervals chosen by your clinician. Some effects appear early; others can emerge later, even after stopping. Keep a simple symptom diary, attend all follow-ups, and contact your team promptly if issues arise. Staying on the planned schedule, when safe, helps your team evaluate how the therapy is working.

Education resources and survivorship programs can support day-to-day needs during care. For broader lung health context, you may also find our article World Lung Day Raising Awareness helpful.

Compare With Alternatives

Checkpoint inhibitors and targeted agents may be considered depending on cancer type and biomarkers. Another PD-L1 antibody, Bavencio®, is used in select settings and has different combination partners. For EGFR-mutated non-small cell lung cancer, the targeted TKI Tagrisso® is an established option for appropriate patients. Your oncology team will choose based on tumor characteristics, prior therapy, and guideline recommendations.

Pricing and Access

We support access with Canadian sourcing and transparent quotes for US shipping from Canada. For cash-pay inquiries, we can share current Imfinzi price without insurance alongside dispensing details and documentation needed by your clinic. Pricing varies by vial size, regimen, and program agreements. To see current options and pharmacy availability, contact us for a personalized quote. If you are exploring coupons, see our current offers on Promotions. Checkout uses encrypted processes to protect your information.

Availability and Substitutions

Supply can fluctuate. If a specific vial size is not available, your prescriber or infusion center may offer an alternative schedule or therapeutic option. Questions about Imfinzi Canadian pricing often relate to vial configuration and clinic preparation requirements. We coordinate closely with your care team before any change to ensure continuity and safety.

Patient Suitability and Cost-Saving Tips

Good candidates are those whose diagnosis and prior treatment match approved indications and who can attend regular infusion visits. Those with uncontrolled autoimmune disease, prior severe immune-related toxicity, or active infections may require alternative approaches. Discuss goals, other therapies, and monitoring needs with your clinician.

• Multi-visit planning: book infusions in advance to align labs and imaging.
• Clinic coordination: confirm how your center procures and prepares vials.
• Financial review: ask about durvalumab self pay programs and assistance.
• Budgeting help: we can discuss Durvalumab cost per dose by regimen.
• Refill reminders: set calendar alerts to avoid scheduling gaps.

Questions to Ask Your Clinician

• Is my cancer type and stage appropriate for this therapy?
• What are the goals of treatment at this time?
• Which side effects should I report immediately, and how are they managed?
• How will infusion timing fit with my other medicines and procedures?
• What imaging and labs will we use to monitor progress?
• If I must pause treatment, how do we restart safely?

Authoritative Sources

For full details, review official resources:

• AstraZeneca Product Information
• FDA DailyMed
• Health Canada Drug Product Database

Who It’s For: Related Conditions

Learn more about specific disease areas we cover:

• Non Small Cell Lung Cancer
• Small Cell Lung Cancer
• Cancer

What to Read Next

For broader oncology context, see National Cancer Control Month Raising. These materials complement, not replace, the official label and your clinician’s guidance.

Ready to proceed? Request a quote and clinic coordination for US delivery from Canada with prompt, express shipping. Prescription required. This information is educational and not a substitute for professional medical advice.